T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D-959 and has initiated pre-clinical studies in Huntington’s Disease models.
View Top Employees from T3D Therapeutics, Inc.| Website | http://www.t3dtherapeutics.com |
| Revenue | $5 million |
| Funding | $16.4 million |
| Employees | 14 (7 on RocketReach) |
| Founded | 2013 |
| Address | 68 T W Alexander Drive, Durham, North Carolina 27709, US |
| Phone | (919) 237-4897 |
| Technologies |
JavaScript,
HTML,
PHP
+9 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing, Finance General, Biotechnology, Drug Discovery, Finance, Science and Engineering, Medical, Health Care, Therapeutics |
| Competitors | Cloud Pharmaceuticals, Inc., Corbus Pharmaceuticals, DelMar Pharmaceuticals, Diasome Pharmaceuticals, Inc., Hua Medicine |
Looking for a particular T3D Therapeutics, Inc. employee's phone or email?
T3D Therapeutics, Inc. Questions
The T3D Therapeutics, Inc. annual revenue was $5 million in 2024.
Jessica Stanek is the Director, Clinical Development of T3D Therapeutics, Inc..
7 people are employed at T3D Therapeutics, Inc..
T3D Therapeutics, Inc. is based in Durham, North Carolina.
Top T3D Therapeutics, Inc. Employees
-
14
-
13
-
24
-
5+5+
-
ViewJessica Stanek
Director, Clinical Development at T3D Therapeutics, Inc.
San Diego, California, United States12
Related Companies
